Recruiting INTERVENTIONAL NCT06233942

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Sponsor: BeOne Medicines

Conditions Advanced Solid Tumor

Interventions BG-C9074 Bevacizumab Tislelizumab

Updated 21 times since 2024 Last updated: Apr 14, 2026 Started: Apr 12, 2024 Primary completion: Sep 28, 2027 Completion: May 15, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06233942, this observational or N/A phase trial focuses on Advanced Solid Tumor and remains actively recruiting participants. Sponsored by BeOne Medicines, it has been updated 21 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

21 versions recorded

Apr 16, 2026 — Present [daily]

Recruiting

Phase: PHASE1 → None
Mar 2026 — Apr 2026 [monthly]

Recruiting PHASE1
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE1
Dec 2025 — Feb 2026 [monthly]

Recruiting PHASE1
Oct 2025 — Dec 2025 [monthly]

Recruiting PHASE1

▶ Show 16 earlier versions

Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE1
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE1
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE1
May 2025 — Jun 2025 [monthly]

Recruiting PHASE1
Apr 2025 — May 2025 [monthly]

Recruiting PHASE1
Feb 2025 — Apr 2025 [monthly]

Recruiting PHASE1
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE1
Nov 2024 — Jan 2025 [monthly]

Recruiting PHASE1
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE1
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Mar 2024 — Jun 2024 [monthly]

Not Yet Recruiting PHASE1
Feb 2024 — Mar 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.

Contact Information

Sponsor contact:

BeOne Medicines

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Baltimore, United States , Beijing, China , Blacktown, Australia , Brasília, Brazil , Clayton, Australia , Columbus, United States , Dalian, China , Fuzhou, China , Guangzhou, China and 28 more locations